Mesoblast Limited (ASX: MSB) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Mesoblast Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Mesoblast Limited (ASX: MSB)
Latest News
Share Market News
ASX 200 Weekly Wrap: ASX 200 on track for a top month
⏸️ ASX Shares
These are the 10 most shorted shares on the ASX
Share Market News
Top brokers name 3 ASX shares to sell next week
Share Gainers
These were the best performing ASX 200 shares last week
Share Market News
The 13 ASX shares that could have doubled your money in 2020
Share Market News
ASX 200 up 0.8%: Fisher & Paykel Healthcare impresses, Harvey Norman's profits surge
Share Fallers
Why Mesoblast, Temple & Webster, Xero, & Zip shares are dropping lower
Share Gainers
Why Brickworks, Mesoblast, Qantas, & Telix shares are storming higher
Share Gainers
Why the Mesoblast (ASX:MSB) share price rocketed 17% higher
Share Gainers
Why Ampol, Cann, Fortescue, & Mesoblast shares are surging higher
Share Market News
ASX 200 Weekly Wrap: ASX continues to climb, despite outage
⏸️ ASX Shares
Here are the 10 most shorted shares on the ASX
Frequently Asked Questions
-
No, Mesoblast does not pay shareholder dividends at this time.
-
Yes, Mesoblast is listed on the ASX and the US Nasdaq under the ticker code NASDAQ: MESO.
-
Mesoblast Ltd listed on the ASX on 16 December 2004.
MSB ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Mesoblast Limited
Mesoblast Ltd (ASX: MSB) is a clinical-stage biotechnology company. It develops and commercialises allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care.
Its portfolio of Phase 3 product candidates includes its flagship remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD) as well as moderate to severe acute respiratory distress syndrome (ARDS). Its other candidates include REVASCOR® for advanced chronic heart failure and MPC-06-ID for chronic low back pain due to degenerative disc disease. These cell therapy candidates are towards the latter stages of their clinical trial pipelines.
Mesoblast has locations in Australia, the United States, and Singapore and is dual-listed on the ASX and the US Nasdaq (NASDAQ: MESO).
